Capricor Shares Rose on Positive Deramiocel Trial Data

The drug showed a slower decline in upper-limb function for DMD patients, ahead of an FDA decision in November.

Updated on Sept. 30, 2026 in Biotech

Isometric editorial illustration showing a glass vial on a clean laboratory surface, representing pharmaceutical clinical research progress. — Capricor Therapeutics shares rose 20 percent on Tuesday after clinical data showed that its investigational cell therapy, Deramiocel, slows the progression of Duchenne muscular dystrophy. AI Illustration. Upload story photo >

Live Poll

Do you rely on your own interpretation of clinical study results when making investment decisions?

Capricor Therapeutics shares climbed 20 percent in after-hours trading on September 29, 2026, following the release of new clinical trial data for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel. The results show significant functional benefits for patients who switched from a placebo to the drug during an extension study.

Why it matters

The clinical findings provide a potential lifeline for the company after a 70 percent decline in its share price year-to-date. Market confidence now hinges on the upcoming regulatory review by the U.S. Food and Drug Administration.

In the 24-month Hope-3 extension study, patients switching from placebo to Deramiocel demonstrated a 76 percent slower decline in upper-limb function and a 66 percent reduction in elbow-related function decline compared to their initial year on placebo.

The players

Capricor Therapeutics

A biotechnology company focused on developing cell-based therapies and exosomes for Duchenne muscular dystrophy and cardiac diseases.

U.S. Food and Drug Administration

The federal agency responsible for regulating pharmaceuticals and determining the market eligibility of new medical treatments.

The details

Deramiocel is an investigational cell therapy designed to address the progression of Duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle weakness. Researchers at the World Muscle Society congress presented findings comparing patients' functional outcomes during their first year on placebo against their subsequent year on the therapy. The data specifically quantifies how the intervention modulates the expected decline of muscle control in the upper limbs.

August 2026: Capricor submitted 24-month Hope-3 extension data to the FDA.
September 29, 2026: CAPR stock fell in the regular session and rose 20 percent after-hours.
September 29 to October 3, 2026: World Muscle Society congress held in Hiroshima.
October 3, 2026: Scheduled Hope-3 presentation on muscle and cardiac efficacy.
November 22, 2026: FDA decision deadline for the Deramiocel application.

The Tech Race

The Hope-3 clinical trial serves as the primary benchmark for assessing the therapeutic potential of Deramiocel in treating muscular dystrophy. The latest 24-month extension data provides a critical data point that informs the ongoing competitive race to bring effective cell therapies to market.

For patients and families affected by Duchenne muscular dystrophy, this development points toward a potential new treatment pathway if the drug receives regulatory clearance. Analysts currently estimate a 40 percent probability of approval, with the final outcome serving as the next major trigger for the company's clinical roadmap.

The takeaway

The latest extension study provides strong evidence that Deramiocel slows the functional deterioration of the upper limbs in patients with Duchenne muscular dystrophy. Investors and the medical community should monitor the official FDA decision due on November 22, 2026, for the final regulatory verdict.